BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

RareCyte Completes Final Tranche of Funding for Launch of its AccuCyte Rare Cell Detection Platform


8/21/2012 11:46:22 AM

SEATTLE--(BUSINESS WIRE)--RareCyte Inc., a Seattle-based life science company, closed the second tranche of its funding led by Telegraph Hill Partners (THP). Founded in 2009, RareCyte is focused on the development of the AccuCyteTM System, a rare cell characterization and retrieval platform based upon the company’s proprietary whole blood enrichment technology. RareCyte’s AccuCyteTM platform is designed to target circulating tumor and circulating endothelial cells through an unbiased approach that results in high recovery and purity for additional downstream analysis of the cells. RareCyte plans to use the funds to complete the final stages of product development and initiate the platform's commercial launch in the research oncology market. “The identification, characterization, enumeration and retrieval of circulating tumor and other rare cells is a complex but critical component in understanding, diagnosing and treating cancer and other blood-related diseases. We see the AccuCyte technology as the premier system enabling these capabilities,” says Robert Shepler, a member of the company’s board of directors and Managing Director at THP. Ron Seubert, President and CEO, adds, “We are pleased to meet the company milestones for our final tranche and look forward to the next stage of the company’s development including the commercial launch of our AccuCyte system.” The AccuCyte system is currently undergoing final testing at the company’s Seattle headquarters through its clinical research partnerships.

Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES